Group 1 - NFT Ltd. has entered into a securities purchase agreement with institutional investors for the purchase and sale of 720,779 units, each consisting of one Class A ordinary share and one warrant, at an effective offering price of $3.85 per unit [1][3] - The gross proceeds from the offering are approximately $2.8 million before deducting fees and expenses, with the offering expected to close on or about March 11, 2026 [3] - The warrants are initially exercisable at a price of $4.17 per share and may be exercised on a zero cash exercise basis, expiring five years from the date of issuance [2] Group 2 - The securities are being offered under a shelf registration statement on Form F-3, which was declared effective by the SEC on November 18, 2025 [4] - NFT Ltd. operates an online platform for trading digital artwork, allowing artists and dealers to access a larger market and generate revenue through listing fees, trading commissions, and management fees [6]

Core Viewpoint - Abits Group Inc has successfully closed a registered direct offering with institutional investors, raising approximately $2.1 million through the sale of Ordinary Shares and pre-funded warrants at a price of $2.65 per share [1][3]. Group 1: Offering Details - The offering included the sale of 792,452 Ordinary Shares or Pre-Funded Warrants, priced at $2.65 per Ordinary Share and $2.64999 per Pre-Funded Warrant, which is the offering price minus an exercise price of $0.00001 [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Financial Proceeds and Use - The aggregate gross proceeds from the offering were approximately $2.1 million, and the transaction closed on February 24, 2026 [3]. - The company plans to utilize the net proceeds from the offering, along with existing cash, for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Aspects - Aegis Capital Corp acted as the exclusive placement agent for the offering, while Kaufman & Canoles, P.C. and Lucosky Brookman LLP served as U.S. counsel for the company and Aegis Capital Corp, respectively [4]. - The offering was conducted under an effective shelf registration statement on Form F-3, previously filed with the U.S. Securities and Exchange Commission (SEC) [4].

Core Insights - E.F. Hutton acted as the exclusive placement agent for a $5 million registered direct offering by VCI Global Limited, a company focused on technology and digital infrastructure solutions [1][2][3] Group 1: Offering Details - The offering is structured in multiple tranches and is expected to generate gross proceeds of $5 million before fees and expenses [2] - The transaction was facilitated with Esousa Group Holdings, LLC, a family office based in New York [2] - The net proceeds from the offering will be used for working capital and general corporate purposes, including the development of technology and digital infrastructure platforms [4] Group 2: Company Background - E.F. Hutton & Co. is an investment bank and broker-dealer headquartered in Manhattan, providing advisory and financing solutions to a diverse range of clients [6] - The firm has a global footprint and offers comprehensive investment banking services, including capital markets, private placements, and M&A advisory [6] - E.F. Hutton's CEO emphasized the firm's commitment to supporting innovative, growth-oriented companies with tailored capital solutions [3]

Core Viewpoint - Insight Molecular Diagnostics Inc. has announced a registered direct offering of 4,525,976 shares of common stock at an offering price of $5.75 per share, expected to raise approximately $26 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on February 12, 2026, pending customary closing conditions [1]. - Lake Street Capital Markets, LLC is acting as the sole placement agent for the offering [2]. - The purchase price for pre-funded warrants is the same as the common stock price, minus an exercise price of $0.0001 per share [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, particularly for research and development in the transplantation category [2]. - The company aims to expand its GraftAssure product line to include heart transplant rejection testing, in addition to kidney transplant rejection testing [3]. Group 3: Shareholder Participation - Bio-Rad Laboratories, Inc., a significant shareholder of Insight Molecular Diagnostics, participated in the offering on the same terms as other investors [3]. Group 4: Regulatory Information - The securities are being offered under a "shelf" registration statement filed with the SEC, which was declared effective on August 7, 2024 [4]. - A final prospectus supplement will be filed with the SEC and will be available on their website [4]. Group 5: Company Overview - Insight Molecular Diagnostics is focused on democratizing access to novel molecular diagnostic testing to improve patient outcomes [6]. - The company offers various products, including GraftAssureCore™, GraftAssureIQ™, and others [6].

Core Viewpoint - Inspira Technologies has announced a registered direct offering of 6,785,715 ordinary shares at a price of $0.70 per share, expected to raise approximately $4.75 million before expenses [1][2]. Group 1: Offering Details - The offering is set to close on or about February 6, 2026, pending customary closing conditions [2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [2]. Group 2: Securities and Registration - The ordinary shares are being offered under a prospectus supplement to be filed with the SEC, linked to the Company's effective shelf registration statement [3]. - The warrants issued in a concurrent private placement will have an exercise price of $0.70 per share and will be exercisable six months after issuance, expiring in 5.5 years [1][3]. Group 3: Existing Warrants Amendment - Existing warrants issued to the investor in December 2023, originally priced at $1.28, will be amended to a reduced exercise price of $0.70 per share, expiring five years from the closing date [5]. Group 4: Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system [6]. - The company is developing the INSPIRA ART500 system for oxygenation while patients remain awake and is advancing the HYLA™ blood sensor platform for continuous, non-invasive monitoring [6]. - With a growing IP portfolio and strategic operational streamlining, Inspira Technologies is positioned as an attractive player in the life-support and MedTech sectors [6].

Core Viewpoint - Innventure, Inc. has successfully closed a registered direct offering of common stock, raising approximately $40 million to strengthen its balance sheet and support its long-term growth strategy [1][3]. Group 1: Offering Details - The offering was made to four institutional investors and resulted in gross proceeds of about $40 million before expenses [1]. - The net proceeds will be used to redeem outstanding convertible debentures and for working capital, including the potential conversion of approximately $8 million of intercompany convertible debt into equity in Accelsius [2]. - The offering was conducted under an effective shelf registration statement filed with the SEC [4]. Group 2: Strategic Implications - The CEO of Innventure emphasized that the capital raised will enhance the company's ability to unlock value from breakthrough technologies and increase ownership in Accelsius, which is positioned in a growing market with a sales opportunity pipeline exceeding $1 billion [3]. - The company aims to drive durable shareholder value as it progresses through future quarters and years [3]. Group 3: Company Overview - Innventure focuses on building companies with billion-dollar valuations by commercializing breakthrough technology solutions and bridging the gap between corporate innovation and commercialization [6].

Core Viewpoint - Innventure, Inc. has entered into securities purchase agreements to sell 11,428,572 shares of common stock for approximately $40 million, aimed at repaying outstanding convertible debentures and for working capital purposes [1][2]. Group 1: Offering Details - The offering is expected to close on or about January 14, 2026, pending customary closing conditions [1]. - Titan Partners is acting as the sole placement agent for the offering [3]. - The offering is made under an effective shelf registration statement on Form S-3, filed with the SEC on December 23, 2025, and declared effective on January 9, 2026 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay all outstanding obligations under convertible debentures and for general corporate purposes, including the repayment of approximately $8 million in intercompany convertible debt [2]. Group 3: Company Overview - Innventure is an industrial growth conglomerate focused on building companies with billion-dollar valuations by commercializing breakthrough technology solutions [6]. - The company aims to bridge the gap between corporate innovation and commercialization through value-driven partnerships and operational expertise [6].

Core Viewpoint - Cemtrex, Inc. has announced a definitive agreement to purchase approximately 1,469,507 shares at a price of $2.722 per share, expecting gross proceeds of $4 million [1]. Group 1: Transaction Details - The transaction is expected to close on or about January 9, 2025, pending customary closing conditions [2]. - The net proceeds from the offering will be used for general corporate purposes, including working capital and potential acquisitions [2]. Group 2: Regulatory Information - The offering is made under an effective shelf registration statement on Form S-3, previously filed with the SEC and declared effective on February 3, 2025 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed terms of the offering [3]. Group 3: Company Overview - Cemtrex, Inc. operates in the Security, Industrial, and Aerospace & Defense sectors, providing advanced security technology and industrial services [6]. - The Security segment, led by Vicon Industries, offers video management software and integrated surveillance solutions [6]. - The Industrial segment provides specialized services such as rigging and equipment installation, while the Aerospace & Defense segment focuses on engineering and instrumentation solutions [6].

Core Viewpoint - ArrowMark Financial Corp. has entered into a securities purchase agreement to sell 673,249 shares of common stock at a price of $22.28 per share, which is slightly above the Net Asset Value of $22.20, indicating a positive impact for current shareholders [1]. Group 1: Offering Details - The registered direct offering is expected to generate proceeds of approximately $14.99 million, excluding legal and administrative expenses [2]. - The offering is conducted under a "shelf" registration statement filed with the SEC, allowing for the sale of securities through a prospectus [3]. Group 2: Company Overview - ArrowMark Financial Corp. is a non-diversified, closed-end fund listed on NASDAQ under the symbol "BANX," with an investment objective focused on providing current income primarily through investments in regulatory capital securities of financial institutions [5].

Core Viewpoint - Mangoceuticals, Inc. has entered into agreements for a registered direct offering and a concurrent private placement, expecting to raise approximately $2.5 million in gross proceeds [1][3]. Group 1: Offering Details - The transactions involve the sale of 1,930,502 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one PIPE Common Warrant at an exercise price of $1.4245 [2]. - The offering price per Common Unit is set at $1.295, while the Pre-Funded Unit is priced at $1.29499, accounting for a minimal exercise price of $0.00001 per Pre-Funded Warrant [2]. - The Pre-Funded Warrants are immediately exercisable and can be exercised at any time until fully exercised [2]. Group 2: Use of Proceeds - The net proceeds from the offerings, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Legal and Regulatory Information - Aegis Capital Corp. is the exclusive placement agent for the offerings, and Lucosky Brookman LLP is acting as counsel to the Company [4]. - The registered direct offering is made under an effective shelf registration statement previously filed with the SEC [4]. - The securities in the private placement are not registered under the Securities Act and are offered only to accredited investors [5]. Group 4: Company Overview - Mangoceuticals, Inc. focuses on developing health and wellness products via a secure telemedicine platform, particularly in men's health sectors such as erectile dysfunction, hair growth, hormone replacement therapies, and weight management [8]. - The telemedicine platform allows consumers to request prescriptions, which are reviewed by a physician and fulfilled through a partner compounding pharmacy [9].